ACAAI: Gene-Editing Therapy Reduces Angioedema Attacks in Hereditary Angioedema

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 24, 2024.

By Elana Gotkine HealthDay Reporter

THURSDAY, Oct. 24, 2024 -- For adults with hereditary angioedema, the in vivo gene-editing therapy NTLA-2002, which is based on clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9, administered as a single dose reduces angioedema attacks, according to a study published online Oct. 24 in the New England Journal of Medicine to coincide with the annual meeting of the American College of Allergy, Asthma & Immunology, held from Oct. 24 to 28 in Boston.

Danny M. Cohn, M.D., Ph.D., from the Amsterdam University Medical Center, and colleagues randomly assigned adults with hereditary angioedema to receive NTLA-2002 in a single dose of 25 mg or 50 mg or placebo in a 2:2:1 ratio (10, 11, and six patients, respectively). The number of angioedema attacks per month from week 1 to 16 was the primary end point.

The researchers found that the estimated mean monthly attack rate was 0.70, 0.65, and 2.82 with 25-mg NTLA-2002, 50-mg NTLA-2002, and placebo, respectively (differences, −75 and −77 percent, respectively, compared with placebo). Overall, 40 and 73 percent of the patients who received 25-mg and 50-mg NTLA-2002, respectively, were attack-free with no additional treatment during the period from weeks 1 to 16. Headache, fatigue, and nasopharyngitis were the most common adverse events among patients receiving NTLA-2002.

"These results show the potential of a single dose of the new CRISPR-Cas9-based in vivo gene editing therapy NTLA-2002 to be a functional cure for patients with hereditary angioedema and support continued investigation in a larger phase 3 trial," the authors write.

The study was funded by Intellia Therapeutics, which is developing NTLA-2002.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-10-25 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords